In one paragraphArticle in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Rahul LakhotiaLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3123-6844 Kieron DunleavyDepartment of Hematology-Oncology, Georgetown University, Washington, DC.
Bayard L PowellDepartment of Internal Medicine-Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC.
Christopher MelaniLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9661-4570 Andrea N LucasLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Seth M SteinbergBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Jonathan W FriedbergWilmot Cancer Institute, University of Rochester, Rochester, NY.
Brad S KahlLymphoma Program, Washington University School of Medicine Siteman Cancer Center, St. Louis, MO.ORCID 0000-0003-0459-6609 Nancy L BartlettLymphoma Program, Washington University School of Medicine Siteman Cancer Center, St. Louis, MO.
Ariela NoyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Mark RoschewskiLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-0278-2635 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MConsortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MRochester Network Lead Academic Participating SiteUG1CA233230 · NCI · UNIVERSITY OF ROCHESTER · PI Paul M Barr · 2019 to 2026
$6.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA086862NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233230NCI NIH HHS UM1 CA121947
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Burkitt LymphomaAdultAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinEtoposideHumansPrednisonePrognosisRituximabVincristineCyclophosphamideDoxorubicinEtoposidePrednisoneRituximabVincristine
Identifiers
PMID37389844
PMCPMC10506053
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390